– 7 Abstracts Highlighting CytomX’s Novel Probody Platform Selected for Oral and Poster Presentations –SOUTH SAN FRANCISCO, Calif., April 29, 2020 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced the selection of seven presentations to be featured as part of the American Society of Clinical Oncology’s (ASCO) ASCO20 Virtual Scientific Program taking place from May 29 – May 31, 2020.
The titles of the abstracts are currently available on ASCO’s 2020 Digital Scientific Program, with full abstracts, including the dates and times of presentations, scheduled for publication on May 13, 2020.A list of accepted abstracts by CytomX and its partners is provided below.ASCO 2020 Clinical Highlights From Across the CytomX Probody PortfolioPreliminary Data from Phase 1/2 Trial of CX-2029, a CD71 Targeting Probody Drug Conjugate, Partnered with AbbViePreliminary Phase 1 Clinical Data Presented by Bristol Myers Squibb from the Ongoing First-in-Human Phase 1/2a trial of BMS-986249, a Probody Version of the anti-CTLA-4 Antibody ipilimumabUpdated Data from the Phase 1/2 Trial of CX-2009, an Anti-CD166 Probody Drug ConjugateUpdated Clinical Data from the Phase 1/2 Trial of CX-072, an Anti-PD-L1 Probody Therapeutic, as Monotherapy, in Selected Tumor Types and in Combination with ipilimumab“Our presence at ASCO this year highlights the strong clinical progress made by CytomX and our partners in exploring the broad potential of the novel Probody technology platform,” said Amy Peterson, M.D., chief development officer of CytomX Therapeutics. “We look forward to updating the oncology community on this progress and on next steps towards our vision of transforming the lives of patients with cancer.”CX-2029, An Anti-CD71 Probody Drug ConjugatePresentation Title: CX-2029, a PROBODY Drug Conjugate Targeting CD71 (Transferrin Receptor): Results from a First-in-Human Study (PROCLAIM-CX-2029) in Patients (Pts) With Advanced Cancer
Session Title: Developmental Therapeutics—Immunotherapy
Abstract: 3502
Session Type: Oral Presentation
CX-072, An Anti-PD-L1 Probody TherapeuticPresentation Title: PROCLAIM-CX-072: Analysis of Patients With Advanced Solid Tumors Receiving Long-Term Treatment With CX-072, a PD-L1 PROBODY Therapeutic, as a Single Agent or in Combination With Ipilimumab.
Session Title: Developmental Therapeutics—Immunotherapy
Abstract: 2005
Session Type: Oral Presentation
Presentation Title: Evidence of Intratumoral Localization, Activation, and Immunomodulatory Effect of CX-072, a PROBODY Therapeutic Targeting PD-L1, in a Phase 1/2 Trial
Session Title: Developmental Therapeutics—Immunotherapy
Abstract: 3108
Session Type: Poster Presentation (Poster #172)
Presentation Title: Preliminary Population Pharmacokinetics Supports Phase 2 Dose Selection for Masked Anti–PD-L1 Antibody CX-072
Session Title: Developmental Therapeutics—Immunotherapy
Abstract: 3602
Session Type: Poster Presentation (Poster #332)CX-2009, An Anti-CD166 Probody Drug ConjugatePresentation Title: CX-2009, A CD166-Directed PROBODY Drug Conjugate (PDC): Results From the First-in-Human Study in Patients With Advanced Cancer Including Breast Cancer
Session Title: Developmental Therapeutics—Immunotherapy
Abstract: 526
Session Type: Poster Presentation (Poster #18)BMS-986249, An Anti-CTLA-4 Probody TherapeuticPresentation Title: Anti–CTLA-4 probody BMS-986249 Alone or in Combination with Nivolumab in Patients with Advanced Cancers: Initial Phase 1 Results
Session Title: Developmental Therapeutics—Immunotherapy
Abstract: 3058
Session Type: Poster Presentation (Poster #122)About CytomX TherapeuticsProbody is a U.S. registered trademark of CytomX Therapeutics, Inc.Christopher Keenan
VP, Investor Relations and Corporate Communications
ckeenan@cytomx.com
650-383-0823
Bay Street News